Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249

AIDS Research and Human Retroviruses
T MelbyMichael Greenberg

Abstract

T-1249 is a peptide HIV fusion inhibitor (FI) previously under development for use in FI-naive and experienced patients. Here we present prospectively planned longitudinal analyses of FI resistance during 48 weeks of T-1249 dosing in patients with extensive prior FI exposure. T1249-105 was a single-arm rollover study in patients with prior resistance to enfuvirtide (ENF) and 10 days of T-1249 functional monotherapy exposure. The phenotype and genotype of plasma virus envelopes were analyzed at baseline and at study weeks 8, 16, and 48. At study entry, viruses had a geometric mean decrease in susceptibility to ENF of 51.8-fold but to T-1249 of 1.8-fold; extensive genotypic resistance to ENF was observed. A median viral load response of - 1.5 log(10) copies/ml was observed at week 2 that was partially sustained (- 0.5 log(10) copies/ml) through 48 weeks. Resistance to T-1249 gradually increased to a geometric mean 92.7-fold decrease from FI-naive baseline; this occurred concomitant with further evolution of gp41 amino acids 36-45, most commonly the G36D (n = 6, 16%) or N43K (n = 9, 24%) substitutions. A novel substitution, A50V (n = 12, 32%), was also common, as were the N126K and S138A substitutions in heptad-repeat 2 (HR-2). Th...Continue Reading

References

Jun 18, 1998·Cell·D C Chan, P S Kim
Dec 23, 1998·Proceedings of the National Academy of Sciences of the United States of America·D C ChanP S Kim
Mar 5, 2004·The Journal of Infectious Diseases·Joseph J EronG Diego Miralles
Aug 31, 2004·Reviews in Medical Virology·Michael GreenbergLynn Smiley
Jan 14, 2005·Current Opinion in Infectious Diseases·Eoin CoakleyJeannette M Whitcomb

❮ Previous
Next ❯

Citations

Jul 21, 2009·The Journal of Biological Chemistry·Dirk EgginkRogier W Sanders
Oct 13, 2010·The Journal of Biological Chemistry·Kazuya ShimuraEiichi N Kodama
Apr 25, 2008·Journal of Virology·Dirk EgginkBen Berkhout
Jan 23, 2009·Journal of Virology·Stéphane HuéUNKNOWN UK Collaborative Group on HIV Drug Resistance
Mar 4, 2009·Annual Review of Biochemistry·Peter M Colman
Jan 25, 2013·Viruses·Christopher J De Feo, Carol D Weiss
Jun 9, 2014·The Journal of Antimicrobial Chemotherapy·Huihui ChongYuxian He
Mar 9, 2010·Journal of the Formosan Medical Association = Taiwan Yi Zhi·Chungen PanShibo Jiang
Mar 24, 2012·Current Opinion in Virology·Ben BerkhoutRogier W Sanders
Jul 21, 2009·Antiviral Research·Luis Menéndez-Arias
Apr 26, 2011·Antiviral Research·Ben Berkhout, Rogier W Sanders
Dec 21, 2011·Antiviral Chemistry & Chemotherapy·Fusako Miyamoto, Eiichi N Kodama
Oct 24, 2019·Retrovirology·Amanda R SmithMichael S Kay

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.